Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent van der Noort

Showing results (81-90 of 108) with videos related to

Pageof 11
Sort By:
The Prostate|September 23, 2015
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relationSushil K Badrising, Vincent van der Noort, Alfons J M van den Eertwegh, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 4, 2023
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancerMirte Muller, Myron G Best, Vincent van der Noort, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2021
Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck RegionDanique M S Berger, Nynke S van den Berg, Vincent van der Noort, et al.
Prostate Cancer and Prostatic Diseases|August 27, 2021
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223Sushil K Badrising, Rebecca D Louhanepessy, Vincent van der Noort, et al.
BJC Reports|November 8, 2024
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational studyChantal F Stockem, Sarah M H Einerhand, Isabel Miras Rodríguez, et al.
European Journal of Cancer (Oxford, England : 1990)|June 26, 2026
Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery ProtocolFlorentine A J Verbeek, Miguel P Martinez, Ilse A C Spiekman, et al.
The Lancet Regional Health. Europe|March 11, 2024
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolKarlijn Verkerk, Birgit S Geurts, Laurien J Zeverijn, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2024
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)Ilse A C Spiekman, Laurien J Zeverijn, Birgit S Geurts, et al.
The Journal of Pathology|July 6, 2022
Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practiceKris G Samsom, Luuk J Schipper, Paul Roepman, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Pageof 11

Showing results (81-90 of 108) with videos related to

Sort By:
Pageof 11
The Prostate|September 23, 2015
Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relationSushil K Badrising, Vincent van der Noort, Alfons J M van den Eertwegh, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 4, 2023
Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancerMirte Muller, Myron G Best, Vincent van der Noort, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 27, 2021
Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck RegionDanique M S Berger, Nynke S van den Berg, Vincent van der Noort, et al.
Prostate Cancer and Prostatic Diseases|August 27, 2021
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223Sushil K Badrising, Rebecca D Louhanepessy, Vincent van der Noort, et al.
BJC Reports|November 8, 2024
Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational studyChantal F Stockem, Sarah M H Einerhand, Isabel Miras Rodríguez, et al.
European Journal of Cancer (Oxford, England : 1990)|June 26, 2026
Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery ProtocolFlorentine A J Verbeek, Miguel P Martinez, Ilse A C Spiekman, et al.
The Lancet Regional Health. Europe|March 11, 2024
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolKarlijn Verkerk, Birgit S Geurts, Laurien J Zeverijn, et al.
European Journal of Cancer (Oxford, England : 1990)|March 12, 2024
Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP)Ilse A C Spiekman, Laurien J Zeverijn, Birgit S Geurts, et al.
The Journal of Pathology|July 6, 2022
Feasibility of whole-genome sequencing-based tumor diagnostics in routine pathology practiceKris G Samsom, Luuk J Schipper, Paul Roepman, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patientsTesa M Severson, Yanyun Zhu, Stefan Prekovic, et al.
Pageof 11